TREATMENT DECISION REGRET IN MEN WITH EARLY-STAGE PROSTATE CANCER: FINDINGS FROM THE UK-WIDE LIFE AFTER PROSTATE CANCER DIAGNOSIS (LAPCD) STUDY.

Sarah Wilding 1, Eila Watson 2 (presenter), Peter Selby 1, William Cross 3, Amy Downing 1, Penny Wright 1, Richard Wagland 1, David Donnelly 4, Adam Glaser 1, *, Anna Gavin 4 * on behalf of the LAPCD study team. *Joint Senior Authors.


Background
• Prostate cancer (PCa) is the most common cancer affecting men in the UK
• Men and their families are frequently presented with a choice at the time of diagnosis between therapeutic strategies that vary in intensity and side effect profile.
• This may result in retrospective regret over the treatment choices made.

Aim:
To investigate which sociodemographic, clinical, and treatment-related factors are associated with decision regret in men with localised prostate cancer.

Methods
• Cross-sectional postal survey of all men diagnosed with PCa in the UK 18-42 months previously.
• Validated patient reported outcomes covering generic and PCa specific domains alongside sociodemographic, psychological and social outcomes.
• Men also completed ‘involvement in decision making’ question.
• Decision regret was assessed using the validated Decision Regret Scale (Brehaut et al., 2003).

Decision regret scale
1. It was the right decision
2. I regret the decision that was made
3. I would make the same decision if I had to do it again
4. The decision did me a lot of harm
5. The decision was a wise one

The decision regret scale is scored out of 100.

Decision regret was categorised as:
No regret
Mild regret
Moderate/Severe regret

Results
• 12,857 men with localised disease completed the Decision Regret Scale.

37% of men report no decision regret
43% of men report mild regret
20% reported moderate/severe regret

Multivariate ordinal regression found involvement in treatment decision making as the factor with the strongest association with decision regret.

Men who indicated they were ‘definitely’ involved in decision making were less likely to report regret than those who reported they were involved ‘to some extent’ (OR, 4.52, 95% CI 4.17-4.90) or were not involved (OR, 6.06, 95% CI 5.08, 7.22).

• Androgen Deprivation Therapy, non-white ethnicity, being unemployed and having ≥3 co-morbidities were also associated with greater regret.

Conclusions
• Involvement in decision making is key to experience of treatment decision regret.
• It is important to assess the level of involvement men desire and tailor the clinical decision making process.

Acknowledgements
The authors thank all the men who completed surveys. This study is based in part on information collected and quality assured by the cancer registries in each nation. This work uses data provided by patients and collected by health services as part of their care and support.

Funding statement: The Life After Prostate Cancer Diagnosis study was funded by the Movember Foundation, in partnership with Prostate Cancer UK, as part of the Prostate Cancer Outcomes programme, grant number BO26/MO12,857 men with localised disease completed the Decision Regret Scale.

Levels of regret reported by perceived involvement in decision making

Proportion (%) reporting each level of decision regret
No regret Mild regret Moderate/Severe regret

0 20 40 60 80 100

Yes, definitely Yes, to some extent Not taken into account Unsure

Men who indicated they were ‘definitely’ involved in decision making were less likely to report regret than those who reported they were involved ‘to some extent’ (OR, 4.52, 95% CI 4.17-4.90) or were not involved (OR, 6.06, 95% CI 5.08, 7.22).

• Androgen Deprivation Therapy, non-white ethnicity, being unemployed and having ≥3 co-morbidities were also associated with greater regret.